Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
Treatment details for leukemia are constantly evolving, and Liv Hospital offers a full spectrum of cutting‑edge options tailored to each patient’s unique disease profile. Whether you are newly diagnosed or seeking a second opinion, this page provides a clear roadmap of the therapies, diagnostic steps, and supportive services available to international patients. In 2022, global survival rates for certain leukemia subtypes improved by more than 15% thanks to advances such as targeted agents and cellular therapies—an encouraging trend that underscores the importance of personalized care.
Our multidisciplinary team combines expertise in hematology, oncology, genetics, and transplant medicine to create a cohesive treatment plan. From initial laboratory work‑up to post‑remission monitoring, every step is coordinated through our 360‑degree patient services, ensuring seamless logistics for travelers coming from abroad. Below you will find detailed sections covering each major treatment modality, supportive care strategies, and the comprehensive support system that makes Liv Hospital a trusted destination for leukemia care.
Understanding the full range of treatment details empowers patients and families to make informed decisions, ask the right questions, and engage confidently with their care team. Continue reading to explore each therapeutic avenue and learn how our international patient program simplifies the journey from diagnosis to recovery.
Leukemia encompasses a group of blood cancers that require a nuanced approach based on the specific subtype—acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). At Liv Hospital, the foundational treatment details include chemotherapy regimens, radiation therapy when indicated, and newer biologic agents. The choice of initial therapy hinges on factors such as patient age, genetic mutations, disease burden, and overall health.
Key components of the treatment plan are:
Our oncology pharmacists collaborate closely with physicians to adjust dosages and manage drug interactions, especially for patients receiving multiple concurrent agents. Below is a comparative table illustrating typical first‑line regimens for the most common leukemia subtypes:
These treatment details serve as a baseline from which our specialists can incorporate newer modalities, such as targeted therapies and immunotherapies, to improve outcomes.
Over the past decade, targeted agents and immunotherapies have reshaped the leukemia treatment landscape. By focusing on specific molecular abnormalities, these therapies offer higher efficacy with reduced systemic toxicity. At Liv Hospital, we integrate these advances into the overall treatment details for eligible patients, guided by comprehensive genomic profiling.
Key targeted and immune‑based options include:
Before initiating any targeted approach, we perform next‑generation sequencing (NGS) and fluorescence in situ hybridization (FISH) to identify actionable mutations. The following checklist outlines the diagnostic steps required to match patients with the appropriate therapy:
Integrating these precision medicines into the broader treatment details not only improves remission rates but also reduces the intensity of conventional chemotherapy for many patients.
Effective leukemia therapy extends beyond anti‑cancer drugs; managing side effects and maintaining quality of life are integral to the overall treatment details. Liv Hospital’s supportive care team includes hematology nurses, nutritionists, physiotherapists, and psychosocial counselors who address the full spectrum of patient needs.
Common supportive interventions include:
Our nutrition specialists create individualized meal plans that consider chemotherapy‑induced taste changes and metabolic demands. The following checklist helps patients track supportive measures during treatment cycles:
By embedding these supportive strategies into the overall treatment details, we aim to minimize treatment interruptions and enhance overall outcomes.
Allogeneic hematopoietic stem cell transplantation (HSCT) remains a potentially curative option for high‑risk or relapsed leukemia. Liv Hospital’s transplant unit follows international standards, offering both matched sibling and unrelated donor programs, as well as haploidentical (half‑matched) transplantation for patients lacking a fully compatible donor.
Critical steps in the transplantation pathway include:
Our success metrics are transparent: the 2‑year overall survival for adult AML patients undergoing HSCT at Liv Hospital exceeds 55%, aligning with leading global centers. The table below compares myeloablative versus reduced‑intensity conditioning regimens:
These treatment details are discussed in depth with patients and families during pre‑transplant counseling, ensuring informed consent and realistic expectations.
Accurate diagnosis and risk stratification are the foundation of personalized leukemia care. At Liv Hospital, each patient follows a systematic diagnostic pathway that feeds directly into a customized treatment plan.
Steps in the pathway:
The resulting plan outlines the sequence of therapies, timing of transplant evaluation, and integration of targeted agents. Below is a simplified flowchart presented as a table to illustrate decision points:
These comprehensive treatment details ensure that each patient receives therapy aligned with the latest scientific evidence and their individual disease biology.
Liv Hospital’s 360‑degree international patient program removes logistical barriers, allowing patients from around the world to focus solely on their health. Our dedicated coordinators manage every aspect of the journey, from the moment the first inquiry arrives until post‑treatment follow‑up.
Key services include:
Patients also receive a welcome packet containing medication schedules, emergency contact numbers, and cultural orientation material. The table below compares our three primary accommodation packages:
By integrating these logistical supports into the overall treatment details, Liv Hospital ensures that international patients experience a seamless, stress‑free pathway to world‑class leukemia care.
Liv Hospital is a JCI‑accredited, internationally recognized center that combines state‑of‑the‑art technology with a patient‑centric approach. Our multidisciplinary teams, advanced laboratory capabilities, and dedicated international services make us a trusted destination for leukemia treatment worldwide.
Ready to discuss your personalized leukemia treatment plan? Contact our international patient office today to schedule a virtual consultation and start your journey toward recovery.
Send us all your questions or requests, and our expert team will assist you.
The treatment program begins with induction chemotherapy to achieve remission, followed by consolidation or maintenance phases depending on the disease. Targeted therapies such as tyrosine‑kinase inhibitors for CML or FLT3 inhibitors for AML are added when specific mutations are identified. Immunotherapies, including monoclonal antibodies and CAR‑T cell therapy, are available for eligible patients. For high‑risk or relapsed cases, allogeneic hematopoietic stem cell transplantation is offered, with both myeloablative and reduced‑intensity conditioning options.
Supportive care is integrated throughout the treatment journey. Patients receive tailored antimicrobial prophylaxis to prevent infections during neutropenia, G‑CSF to shorten low‑white‑cell periods, and blood product support with strict compatibility checks. Pain and nausea are managed using WHO analgesic ladders and anti‑emetic protocols. Nutritionists create individualized meal plans, while physiotherapists and counselors address physical deconditioning and emotional wellbeing, helping maintain treatment adherence and quality of life.
Allogeneic hematopoietic stem cell transplantation (HSCT) is evaluated after the diagnostic work‑up and risk classification. Candidates include patients with high‑risk cytogenetics, measurable residual disease after induction, or those who relapse after standard therapy. The transplant pathway includes donor search, HLA typing, conditioning (myeloablative for younger, fit patients or reduced‑intensity for older/comorbid patients), stem‑cell collection, and post‑transplant immunosuppression to prevent graft‑versus‑host disease. Liv Hospital reports a 2‑year overall survival >55% for adult AML patients undergoing HSCT.
Before initiating targeted agents, Liv Hospital performs a comprehensive molecular work‑up. This includes next‑generation sequencing covering over 50 leukemia‑related genes to detect mutations such as FLT3‑ITD or BCR‑ABL. Fluorescence in situ hybridization (FISH) identifies translocations like t(9;22). Bone‑marrow aspirate with flow cytometry determines immunophenotype, and standard labs (CBC, chemistry) assess organ function. The results guide the selection of TKIs, FLT3 inhibitors, BTK inhibitors, or monoclonal antibodies, ensuring the therapy matches the patient’s molecular profile.
International patients benefit from a dedicated program that streamlines every step of their journey. The team arranges airport transfers, visa documentation, and hotel bookings near the hospital. They coordinate diagnostic appointments, treatment schedules, and transplant evaluations, providing a single point of contact for language translation and cultural support. This comprehensive approach reduces stress for patients and families, allowing them to focus on treatment and recovery.
Your Comparison List (you must select at least 2 packages)
